Edwards Lifesciences Corporation
EW
Kedudukan dalam Saham
#480
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Harga Saham
$87.54
Modal Pasaran
$50.46B
Perubahan (1 hari)
1.25%
Perubahan (1 tahun)
17.28%
Negara
US
Perdagangan Edwards Lifesciences Corporation (EW)
Kategori
Healthcare
Pendapatan untuk Edwards Lifesciences Corporation (EW)
Pendapatan pada Jun 2026 TTM: $1.42B
Menurut laporan kewangan terkini Edwards Lifesciences Corporation, pendapatan semasa syarikat ialah $1.42B. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $1.55B, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $1.37B. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Edwards Lifesciences Corporation dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $1.42B | 11.37% |
| 2025 | $1.27B | -17.78% |
| 2024 | $1.55B | 12.80% |
| 2023 | $1.37B | -22.35% |
| 2022 | $1.77B | 3.84% |
| 2021 | $1.70B | 85.67% |
| 2020 | $916.70M | -21.41% |
| 2019 | $1.17B | 53.20% |
| 2018 | $761.40M | -26.43% |
| 2017 | $1.03B | 40.25% |
| 2016 | $737.90M | 18.56% |
| 2015 | $622.40M | -45.59% |
| 2014 | $1.14B | 122.01% |
| 2013 | $515.30M | 31.76% |
| 2012 | $391.10M | 37.91% |
| 2011 | $283.60M | 5.74% |
| 2010 | $268.20M | -11.89% |
| 2009 | $304.40M | 85.16% |
| 2008 | $164.40M | 9.75% |
| 2007 | $149.80M | -13.06% |
| 2006 | $172.30M | 47.64% |
| 2005 | $116.70M | 287.71% |
| 2004 | $30.10M | -67.56% |
| 2003 | $92.80M | 65.71% |
| 2002 | $56.00M | -722.22% |
| 2001 | $-9.00M | -96.53% |
| 2000 | $-259.00M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $7.51B | 429.84% |
US
|
|
| $5.56B | 292.42% |
IE
|
|
| $5.15B | 263.15% |
US
|
|
| $3.86B | 172.36% |
US
|
|
| - | - |
DE
|
